Efficacy of Nivolumab plus Ipilimumab in Advanced Hepatocellular Carcinoma with and without High-Risk Features: An International Multicenter Study.

Exploratory analyses showed an overall trend toward more frequent any-grade TRAEs in the nivolumab 1 mg/kg plus ipilimumab 3 mg/kg group.

also in 4,871 other papers

Notably, when patients were stratified based on intrahepatic tumor burden (none, <25%, 25%–50%, and ≥50%), a clear trend of progressively worse prognosis with increasing tumor burden was observed.

also in 19,460 other papers